In the development and production of gene therapy formulations, if antibiotics are used to inhibit bacterial contamination in the steps of cell culture and virus production, antibiotic residues may exist in the final gene therapy formulations. Although antibiotics can prevent bacterial contamination, if the antibiotic residues are not strictly controlled, a series of safety problems may be caused, which may affect the safety of the products. Therefore, ensuring that antibiotic residues in gene therapy formulations meet safety standards is an important part of product quality control.
CD Formulation has established an advanced and complete technology platform for impurity testing of gene therapy formulations, and the antibiotic residue testing we provide plays an important role in helping researchers to strictly control the antibiotic residue in the final product and ensure the safety of gene therapy formulations.
Antibiotic residue measurement is one of the key aspects of impurity testing associated with gene therapy formulation processes. Accurate measurement of residual antibiotic levels in gene formulations is important for various reasons.
We offer a comprehensive range of antibiotic residue assay services for gene therapy formulations to help you ensure that your products meet the required quality and safety standards. The specific services we provide include the following.
We provide individualized determination solutions for a wide range of antibiotics commonly used in the production of different gene therapy formulations, such as penicillin, streptomycin, gentamicin, kanamycin, and so on.
HPLC is currently one of the standard methods for the detection of antibiotic residues, capable of accurately differentiating and quantifying different types of antibiotic residues. Using the HPLC method, we can accurately determine different antibiotic residues in gene therapy formulations.
We offer extremely sensitive assays to ensure that even trace amounts of antibiotic residues can be accurately detected to meet stringent regulatory requirements.
Upon completion of the assay, we provide a detailed assay report, and all of our data support meets regulatory requirements for the development and manufacture of gene therapy formulations.
We can provide customized antibiotic residue assays for different gene therapy formulations to ensure that the assay is precisely matched to your product process.
Antibiotic residues are detected by various methods, different methods have their own advantages and limitations, in antibiotic residue testing, we will combine the characteristics of the product and customer needs, choose the most suitable method, the following list of some of our most commonly used techniques.
Platforms & Technologies | Content Description |
---|---|
Microbial detection method | Antibiotics are detected by observing the life activities of microorganisms, mainly based on the size of the ring of inhibition produced in the sample under test to determine the antibiotic residue status in the sample. This method can intuitively and specifically reflect the antibacterial activity of antibiotics. |
Enzyme-linked immunosorbent assay (ELISA) | This is a detection method based on the specific binding of antigen and antibody, which has the advantages of high sensitivity, high specificity and easy operation. |
Fluorescence immunoassay (FIA) and radioimmunoassay (RIA) | These methods are also based on an immune response and we detect antibiotic residues by using different markers. |
High performance liquid chromatography (HPLC) | This is a commonly used quantitative analytical method with the advantages of high speed, high efficiency and high sensitivity. HPLC has shown good application in the detection of many antibiotics. |
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) | We combine the rapid analytical capability of liquid chromatography with the structure-confirming property of mass spectrometry to accurately characterize and quantify the components of complex mixtures. |
Technology: Antibiotic residue testing
Journal: Int J Stem Cells
Published: 2023
The article discusses the advancements in ex-vivo gene therapy aimed at improving mesenchymal stem cells (MSCs) by introducing functional genes in a laboratory setting. It focuses on the use of selection markers to enhance gene delivery efficiency and assesses the associated risks in the manufacturing process. Specifically, the study examines MSCs engineered to carry the cytosine deaminase gene (CD) and a puromycin resistance gene (PuroR) as a selection marker. Results indicate that the therapeutic efficacy of MSCs/CD is linked to their purity, as the PuroR gene effectively eliminates unmodified MSCs, thereby enhancing overall purity during production. The researchers also created a puromycin-resistant E. coli strain to simulate in vivo horizontal gene transfer and tested its antibiotic susceptibility. Findings suggest that clinically available antibiotics can effectively manage the risk of transferring antibiotic resistance genes. Overall, the study underscores the benefits of using the PuroR gene to improve the quality and effectiveness of MSC-based gene therapies while addressing safety concerns regarding antibiotic resistance.
CD Formulation follows the forefront of quality control of gene therapy formulations and continuously optimizes its technology system to provide researchers with accurate and reliable technical support and solutions for antibiotic residue testing of gene therapy formulations. If you are interested in us, please feel free to contact us.
References